COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)

Francesco Marchesi , Jon Salmanton-García , Ziad Emarah , Klára Piukovics , Marcio Nucci , Alberto López-García , Zdeněk Ráčil , Francesca Farina , Marina Popova , Sofia Zompi , Ernesta Audisio , Marie-Pierre Ledoux , Luisa Verga , Barbora Weinbergerová , Tomas Szotkovski , Maria Gomes da Silva , Nicola Fracchiolla , Nick de Jonge , Graham Collins , Monia Marchetti , Gabriele Magliano , Carolina García-Vidal , Monika Biernat , Jaap van Doesum , Marina Machado , Fatih Demirkan , Murtadha Al-Khabori , Pavel Žák , Benjamín Víšek , Igor Stoma , Gustavo-Adolfo Méndez , Johan Maertens , Nina Khanna , Ildefonso Espigado , Giulia Dragonetti , Luana Fianchi , Maria Ilaria del Principe , Alba Cabirta , Irati Ormazabal-Vélez , Ozren Jaksic , Caterina Buquicchio , Valentina Bonuomo , Josip Batinić , Ali Omrani , Sylvain Lamure (1, 2) , Olimpia Finizio , Noemí Fernández , Iker Falces-Romero , Ola Blennow , Rui Bergantim , Natasha Ali , Sein Win , Jens van Praet , Maria Chiara Tisi , Ayten Shirinova , Martin Schönlein , Juergen Prattes , Monica Piedimonte , Verena Petzer , Milan Navrátil , Austin Kulasekararaj , Pavel Jindra , Jiří Sramek , Andreas Glenthøj , Rita Fazzi , Cristina de Ramón-Sánchez , Chiara Cattaneo , Maria Calbacho , Nathan Bahr , Shaimaa El-Ashwah , Raul Cordoba , Michaela Hanakova , Giovanni Zambrotta , Mariarita Sciumè , Stephen Booth , Raquel Nunes Rodrigues , Maria Vittoria Sacchi , Nicole García-Poutón , Juan-Alberto Martín-González , Sofya Khostelidi , Stefanie Gräfe , Laman Rahimli , Emanuele Ammatuna , Alessandro Busca , Paolo Corradini , Martin Hoenigl , Nikolai Klimko , Philipp Koehler , Antonio Pagliuca , Francesco Passamonti , Oliver Cornely , Livio Pagano

1 CHU Montpellier
2 IGMM - Institut de Génétique Moléculaire de Montpellier

Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p

Domaines: Immunologie; Cancer; Hématologie

Francesco Marchesi, Jon Salmanton-García, Ziad Emarah, Klára Piukovics, Marcio Nucci, et al.. COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA). Haematologica, 2022, ⟨10.3324/haematol.2022.280847⟩. ⟨hal-03791177⟩